Mark de Souza
Mark P. de Souza, PhD is a consultant at Shire HGT and is President, CEO and founder of Lotus Tissue Repair and serves as its president and chief executive officer. Lotus was acquired by Shire HGT in early 2013. Mark has more than 15 years of early stage biotechnology company and academic experience. Prior to founding Lotus, he was Vice President of Business Development at Dyax Corp, a biopharmaceutical company which discovered, developed and commercializes KALBITOR®, its lead product in hereditary angioedema, an orphan genetic disease. He joined Dyax in 2001 as Director of Technology Marketing. Since 2003, he led the business development team, which was responsible for licensing Dyax's phage display technology and products, including KALBITOR®, generating greater than $200 million in license fees and other forms of financing from 50+ technology and product licensing transactions.
Lotus Tissue Repair developed its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating wound healing. The company's lead program is the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), a devastating orphan disease with no currently approved treatment options other than palliative care. Dystrophic epidermolysis bullosa (DEB) is a rare genetic skin disorder characterized by skin fragility, separation of the epidermis from the dermis (which results in blister formation), milia and scarring of varying clinical severity.